New Antibiotics in the Therapy of Osteomyelitis

• Main Authors: Stefanie HIRSIGER, İlke ILGAZ, İlker UÇKAY
• Format: Article
• Language: Turkish
• Published: Galenos Yayinevi 2017-12-01
• Series: Mediterranean Journal of Infection, Microbes and Antimicrobials
• Subjects: Osteomiyelit; antibiyotik tedavisi; yenilikler; hiperbarik oksijen; nemanoxacin
• Online Access: http://www.mjima.org/pdf.php?&id=97

Osteomyelitis is probably the oldest known infection in the history of life. It can develop secondary to local tissue disruption, ischemia and associated chronic wounds or via hematogenous infection. Although it has been known to the medical community for a long time, treatment remains challenging. Detection of the microbial agent remains crucial for the associated antibiotic therapy. Also, tissue specimens for culture and histology must be obtained. Several factors such as biofilm formation, resistance development and special virulence factors can impede the efficiency of the antibiotic treatment. In the last two decades, developments of antibiotic agents with available data in the field of osteomyelitis primarily include brilacidin, ceftaroline, ceftobiprole, dalbavancin, daptomycin, tedizolid, telavancin, tigecycline. Many of them are not on the market, or under study, or only found in selected countries. However, they are expected to become more accessible in coming years.